JP2024516929A - 眼用ラキニモド製剤 - Google Patents

眼用ラキニモド製剤 Download PDF

Info

Publication number
JP2024516929A
JP2024516929A JP2023557096A JP2023557096A JP2024516929A JP 2024516929 A JP2024516929 A JP 2024516929A JP 2023557096 A JP2023557096 A JP 2023557096A JP 2023557096 A JP2023557096 A JP 2023557096A JP 2024516929 A JP2024516929 A JP 2024516929A
Authority
JP
Japan
Prior art keywords
formulation
pharma
ceutically acceptable
mpas
laquinimod
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023557096A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516929A5 (enExample
Inventor
ウェンマン，ハンス
トルングレーン，マリー
エリクソン，ヘレナ
ブール，アンドレアス
Original Assignee
アクティブ バイオテック エイビー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクティブ バイオテック エイビー filed Critical アクティブ バイオテック エイビー
Publication of JP2024516929A publication Critical patent/JP2024516929A/ja
Publication of JP2024516929A5 publication Critical patent/JP2024516929A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023557096A 2021-04-01 2022-03-31 眼用ラキニモド製剤 Pending JP2024516929A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21166691.2 2021-04-01
EP21166691 2021-04-01
PCT/EP2022/058523 WO2022207773A1 (en) 2021-04-01 2022-03-31 Laquinimod formulation for ocular use

Publications (2)

Publication Number Publication Date
JP2024516929A true JP2024516929A (ja) 2024-04-18
JP2024516929A5 JP2024516929A5 (enExample) 2025-03-27

Family

ID=75362492

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023557096A Pending JP2024516929A (ja) 2021-04-01 2022-03-31 眼用ラキニモド製剤

Country Status (14)

Country Link
US (1) US20240180819A1 (enExample)
EP (2) EP4461364B1 (enExample)
JP (1) JP2024516929A (enExample)
KR (1) KR20230165260A (enExample)
CN (1) CN117120035A (enExample)
AU (1) AU2022248724A1 (enExample)
BR (1) BR112023018932A2 (enExample)
CA (1) CA3212851A1 (enExample)
ES (1) ES3014261T3 (enExample)
IL (1) IL305997A (enExample)
MX (1) MX2023010971A (enExample)
PL (1) PL4312986T3 (enExample)
WO (1) WO2022207773A1 (enExample)
ZA (1) ZA202309969B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL320428A (en) 2022-11-04 2025-06-01 Qlaris Bio Inc Topical ophthalmic administration of cromolyns
CN118892446A (zh) * 2023-04-27 2024-11-05 维眸生物科技(浙江)有限公司 一种含vvn001的眼科组合物
CN119523881A (zh) * 2024-04-28 2025-02-28 中国人民解放军海军军医大学第二附属医院 一种s100a9抑制剂凝胶剂及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016529297A (ja) * 2013-08-28 2016-09-23 プレスバイオピア・セラピーズ・エル・エル・シー 老視を治療するための組成物及び方法
JP2016537364A (ja) * 2013-11-15 2016-12-01 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いた緑内障の治療
US20170105987A1 (en) * 2015-10-15 2017-04-20 Bridge Pharma, Inc. Formulations and Methods for Treating High Intraocular Pressure
WO2020257663A1 (en) * 2019-06-19 2020-12-24 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
KR20220118419A (ko) 2019-12-19 2022-08-25 액티브 바이오테크 에이비 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016529297A (ja) * 2013-08-28 2016-09-23 プレスバイオピア・セラピーズ・エル・エル・シー 老視を治療するための組成物及び方法
JP2016537364A (ja) * 2013-11-15 2016-12-01 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いた緑内障の治療
US20170105987A1 (en) * 2015-10-15 2017-04-20 Bridge Pharma, Inc. Formulations and Methods for Treating High Intraocular Pressure
WO2020257663A1 (en) * 2019-06-19 2020-12-24 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis

Also Published As

Publication number Publication date
AU2022248724A1 (en) 2023-11-02
MX2023010971A (es) 2023-09-27
KR20230165260A (ko) 2023-12-05
US20240180819A1 (en) 2024-06-06
PL4312986T3 (pl) 2025-02-17
BR112023018932A2 (pt) 2023-10-10
CA3212851A1 (en) 2022-10-06
EP4312986B1 (en) 2024-10-23
EP4461364A3 (en) 2024-11-27
CN117120035A (zh) 2023-11-24
ZA202309969B (en) 2025-03-26
EP4312986C0 (en) 2024-10-23
EP4461364A2 (en) 2024-11-13
EP4461364B1 (en) 2026-04-22
EP4312986A1 (en) 2024-02-07
WO2022207773A1 (en) 2022-10-06
ES3014261T3 (en) 2025-04-21
IL305997A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
US8614178B2 (en) Pharmaceutical composition for treatment of dry eye syndrome
EA034839B1 (ru) Офтальмологический раствор
KR102766771B1 (ko) 국소형 시클로스포린 함유 제형 및 그의 용도
JP2021518352A (ja) チモロールを含む医薬組成物
JP2024516929A (ja) 眼用ラキニモド製剤
JP2021515758A (ja) ネビボロールを含む医薬組成物
US11229596B2 (en) Preservative free pharmaceutical ophthalmic compositions
WO2017066052A1 (en) Formulations and methods for treating high intraocular pressure
US20090169629A1 (en) Micellar compositions with ophthalmic applications
JP2025513090A (ja) 眼疾患の治療のためのミコフェノール酸及び／又はベタメタゾンの医薬組成物
CN111372564B (zh) 用于治疗眼周分泌腺中或眼表上的异常发炎的组合物和方法
US20090170944A1 (en) Ophthalmic micellar compositions with enhanced stability
US20200171124A1 (en) Topical compositions for ophthalmic and otic use
KR20140069210A (ko) 안과적 겔 조성물
HK40102218B (en) Laquinimod formulation for ocular use
HK40102218A (en) Laquinimod formulation for ocular use
EA051540B1 (ru) Композиция лаквинимода для глазного применения
KR20120124059A (ko) 치환된 감마 락탐을 함유하는 안과 제제 및 이의 사용 방법
WO2025133214A1 (en) Ophthalmic polypeptide compositions for the treatment of posterior eye disorders
WO2024129675A1 (en) Tacrolimus compositions and methods of use
EP2077105A1 (en) Ophthalmic Micellar Compositions with Enhanced Stability
EP2077104A1 (en) Micellar compositions with ophtalmic applications
JP2025520875A (ja) 中等度／重度のドライアイ関連眼症状の処置のための安定なペプチド組成物およびその使用方法

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20231113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250317

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260220